Oh those pesky seniors! They never do what they’re supposed to do, at least if you’re a GOP political strategist. Check out this new analysis from Gallup of attitudes toward the Medicare prescription drugs law.
Here’s the most amazing thing: seniors now say they oppose, not favor, the part of the law that should be most popular among them: the new prescription drug benefit. In early December, they narrowly favored it, 46-39. But now, four months later, they say they oppose it, 48-36.
The Gallup analysis also finds that only 26 percent of seniors believe the new law will actually help seniors with their prescription drugs situation, rather than hurt it or have no effect. And only 14 percent of seniors think the bill will help make the Medicare system more financially secure.
Read ’em and weep, Karl.
Note: With this post, I’m off on Spring Break ’til Wednesday. Back with analysis of the latest polling data and other thoughts then.
TDS Strategy Memos
Latest Research from:
Editor’s Corner
By Ed Kilgore
-
July 11: If Biden “Steps Aside” and Harris Steps Up, There Should Be No Falloff in Support
At New York I discussed and tried to resolve one source of anxiety about a potential alternative ticket:
One very central dynamic in the recent saga of Democratic anxiety over Joe Biden’s chances against Donald Trump, given the weaknesses he displayed in his first 2024 debate, has been the role of his understudy, Vice-President Kamala Harris. My colleague Gabriel Debenedetti explained the problem nearly two years ago as the “Kamala Harris conundrum”:
“Top party donors have privately worried to close Obama allies that they’re skeptical of Harris’s prospects as a presidential candidate, citing the implosion of her 2020 campaign and her struggles as VP. Jockeying from other potential competitors, like frenemy Gavin Newsom, suggests that few would defer to her if Biden retired. Yet Harris’s strength among the party’s most influential voters nonetheless puts her in clear pole position.”
The perception that Harris is too unpopular to pick up the party banner if Biden dropped it, but too well-positioned to be pushed aside without huge collateral damage, was a major part of the mindset of political observers when evaluating Democratic options after the debate. But now fresher evidence of Harris’s public standing shows she’s just as viable as many of the candidates floated in fantasy scenarios about an “open convention,” “mini-primary,” or smoke-filled room that would sweep away both parts of the Biden-Harris ticket.
For a good while now, Harris’s job-approval numbers have been converging with Biden’s after trailing them initially. These indicate dismal popularity among voters generally, but not in a way that makes her an unacceptable replacement candidate should she be pressed into service in an emergency. As of now, her job-approval ratio in the FiveThirtyEight averages is 37.1 percent approve to 51.2 percent disapprove. Biden’s is 37.4 percent approve to 56.8 percent disapprove. In the favorability ratios tracked by RealClearPolitics, Harris is at 38.3 favorable to 54.6 percent unfavorable, while Biden is at 39.4 percent favorable to 56.9 percent unfavorable. There’s just not a great deal of difference other than slightly lower disapproval/unfavorable numbers for the veep.
On the crucial measurement of viability as a general-election candidate against Trump, there wasn’t much credible polling prior to the post-debate crisis. An Emerson survey in February 2024 showed Harris trailing Trump by 3 percent (43 percent to 46 percent), which was a better showing than Gavin Newsom (down ten points, 36 percent to 46 percent) or Gretchen Whitmer (down 12 points, 33 percent to 45 percent).
After the debate, though, there was a sudden cascade of polling matching Democratic alternatives against Trump, and while Harris’s strength varied, she consistently did as well as or better than the fantasy alternatives. The first cookie on the plate was a one-day June 28 survey from Data for Progress, which showed virtually indistinguishable polling against Trump by Biden, Harris, Cory Booker, Pete Buttigieg, Amy Klobuchar, Gavin Newsom, J.B. Pritzker, Josh Shapiro, and Gretchen Whitmer. All of them trailed Trump by 2 to 3 percent among likely voters.
Then two national polls released on July 2 showed Harris doing better than other feasible Biden alternatives. Reuters/Ipsos (which showed Biden and Trump tied) had Harris within a point of Trump, while Newsom trailed by three points, Andy Beshear by four, Whitmer by five, and Pritzker by six points. Similarly, CNN showed Harris trailing Trump by just two points; Pete Buttigieg trailing by four points; and Gavin Newsom and Gretchen Whitmer trailing him by five points.
Emerson came back with a new poll on July 9 that wasn’t as sunny as some for Democrats generally (every tested name trailed Trump, with Biden down by three points). But again, Harris (down by six points) did better than Newsom (down eight points); Buttigieg and Whitmer (down ten points); and Shapiro (down 12 points).
There’s been some talk that Harris might help Democrats with base constituencies that are sour about Biden. There’s not much publicly available evidence testing that hypothesis, though the crosstabs in the latest CNN poll do show Harris doing modestly better than Biden among people of color, voters under the age of 35, and women.
The bottom line is that one element of the “Kamala Harris conundrum” needs to be reconsidered. There should be no real drop-off in support if Biden (against current expectations) steps aside in favor of his vice-president (the only really feasible “replacement” scenario at this point). She probably has a higher ceiling of support than Biden as well, but in any event, she would have a fresh opportunity to make a strong first or second impression on many Americans who otherwise know little about her.
It is very simple. I can get health insurance through my employer when I retire (OK I bear the full cost). It includes pharmaceutical insurance. If this idiocy comes into force I can kiss it goodbye and welcome a half assed scheme that will cost more for less coverage.
Basically the HMOs will force anyone covered by this Medidon’tcare idiocy out of their plan and onto George’s.
Very appropriate that your link to “Non Southern Strategy” doesn’t work- because like the link it doesn’t work. Thinking in those terms is a road to nowhere- FAST.
The reason for seniors’ disenchantment is unclear, but the Gallup responses (and simple logic) suggest that seniors think that perscription drug relief should be more generous. Kerry’s predicament is that even the current modest program — conservative price tag $530 billion — will be tough to fund. A popular alternative is to force drug companies to sell their products in the US for the prices charged in Canada (presumably what Kerry means by “fighting the big drug companies.”) But it would be naive to hope that the druggies will not react by cutting expenditures on research and development, especially R&D of drugs that only a small percentage of patients will buy. If we compel the drug companies to charge Wal-Mart prices, we should not expect them to provide Sacks Fith Avenue merchandise. Of course, Congress could follow up with legislation the *encourage* R&D, with tax incentives. In my semi-education opinion, such an approach would (1) cost taxpayers more in the end than simply having the government pay the durg companies the market price for their goods; or (2) be ineffective in fostering R&D at the current robust levels; or (3) both. The old political game — chisel lots of people out of small amounts of money, hoping they don’t notice, and use the proceeds to give a highly publicised free lunch to whoever you are pandering to this month. (Note — I am well aware that the R’s do this as often as the D’s).
On spring break? Does that mean we’ll be seeing you in an upcoming “Emerging Democratic Majority Gone Wild!” video, doing unspeakable things?
iF ANY USE THIS POLL IN PERSUATION OF ONE NOT ALREADY IN THE CHOIRE, DON’T. dON’T SO THAT A DIALOG OF MUTUAL SEARCHING OF AN ISSUE IS SHARED. sHARED SO AS TO JOIN IN COMMON GROUND. fOR IN THE MEDICARE PLAN THE ULTIMATE PRINCIPLES OF THE GOP ARE PLAYED OUT. bUSH IS A MEDIOCRE ARISTOCRATE IN THE PARACITICAL CRONI CAPITALIST aYN RAND VAIN. tHE RELIGIOUS RIGHT USES THE LORDS NAME IN VAIN.